Лубенникова Елена Владимировна
Russian Cancer Research Center NN Blokhin · 46 works · 39 citations · h-index 3
Top works
- Efficacy and safety of cisplatin and paclitaxel (PlaTax regimen) in the neoadjuvant treatment of patients with stage II–III triple-negative breast cancer
- Optimal choice of neoadjuvant therapy for HER2-positive breast cancer. Analysis of doctors’ preferences in Russian Federation
- Russian multicenter experience of using talazoparib in the treatment of patients with BRCA-associated metastatic breast cancer
- Ribociclib for the treatment of hormone-positive HER2-negative breast cancer
- Choice of therapy for HER2-positive metastatic breast cancer in real clinical practice: analysis of physician preferences in Russian Federation
- Choice of adjuvant therapy for HER2-positive breast cancer in real clinical practice: analysis of physician preferences in the Russian Federation
- Improving early breast cancer treatment: the role of granulocyte colony-stimulating factor
- Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer
- Expanding the treatment options for HER2-low metastatic breast cancer: Experience with trastuzumab deruxtecan in aggressive luminal HER2-low breast cancer
- Trastuzumab deruxtecan heralds new era in the treatment of metastatic breast cancer
- Ribociclib in 1st line HR+ breast cancer treatment
- Updated analysis – OlympiA study: Chance of cure in early and locally advanced gBRCA-associated breast cancer
- Abemacyclib is a unique representative of the class of CDK4/6 inhibitors in the treatment of HR+/HER2- metastatic breast cancer
- The dynamics of adjuvant therapy selection for HER2-positive breast cancer in real clinical practice: the third consecutive analysis of physicians’ preferences in the Russian Federation
- Olaparib in the metastatic HER2-negative breast cancer setting
- ERCC1 and XRCC1 as prognostic biomarkers for early HER2-positive breast cancer.
- Therapy of BRCA-associated metastatic breast cancer. Efficacy and safety of talazoparib in the real-world clinical practice
- Clinical outcome of Russian HER2-positive breast cancer patients with brain metastases: Retrospective review.
- Abstract 5975: Long-acting G-CSF empefilgrastim with dose-dense chemotherapy for patients with stage II-III TNBC: Defendor Special trial, primary analysis
- Opyt dlitel'nogo primeneniya kombinatsii kapetsitabina, lapatiniba i trastuzumabapri HER-2-pozitivnom metastaticheskom rake molochnoy zhelezy. Opisanie klinicheskogo sluchaya